预测伊他替尼联合糖皮质激素治疗急性移植物抗宿主病完全缓解的生物标志物特征
研究对25例鉴定队列血浆行广泛蛋白质组学分析筛选候选标志物,并在210例安慰剂对照随机试验验证队列中检验。MCP3、ProCALCA/CALCA与REG3A可区分伊他替尼的完全缓解者与非缓解者,但对安慰剂无此作用;ProCALCA/CALCA、ST2、TNFR1在伊他替尼缓解者中随时间显著下降。
要点
- MCP3、ProCALCA/CALCA与REG3A可区分伊他替尼治疗完全缓解者与非缓解者,对安慰剂无此分层作用。
- ProCALCA/CALCA、ST2、TNFR1在伊他替尼缓解者中随时间显著降低,可能为疗效反应标志物。
- 新标志物有望识别可能对伊他替尼联合糖皮质激素有反应的急性GVHD患者。
核心结论
- 新生物标志物有望识别可能对伊他替尼联合糖皮质激素治疗有反应的急性GVHD患者(NCT02614612;NCT03139604)。
研究设计与样本
- 鉴定队列25例参与者(NCT02614612)血浆样本用于发现新标志物,验证队列来自安慰剂对照随机试验(n=210;NCT03139604)。
- 鉴定队列接受糖皮质激素联合伊他替尼200或300 mg每日一次;验证队列接受糖皮质激素联合伊他替尼200 mg每日一次或安慰剂。
- 采用邻位延伸分析进行广泛蛋白质组学分析,基线与纵向比较分别用非配对t检验和单因素方差分析评估标志物水平变化。
主要发现
- 鉴定出7个候选生物标志物。
- MCP3、ProCALCA/CALCA与既往已知的预后标志物REG3A可将伊他替尼的完全缓解者与非缓解者(疾病进展者)分层,但对安慰剂无此作用,可能代表伊他替尼在急性GVHD中的预测性生物标志物。
- ProCALCA/CALCA、ST2与TNFR1在伊他替尼缓解者中随时间显著降低,可能代表治疗反应性生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A broad proteomic analysis was conducted to identify and evaluate candidate biomarkers potentially predictive of response to treatment with an oral selective Janus kinase 1 (JAK1) inhibitor, itacitinib, in acute graft-versus-host disease (GVHD). Plasma samples from 25 participants (identification cohort; NCT02614612) were used to identify novel biomarkers that were tested in a validation cohort from a placebo-controlled, randomised trial (n = 210; NCT03139604). The identification cohort received corticosteroids plus 200 or 300 mg itacitinib once daily. The validation cohort received corticosteroids plus 200 mg itacitinib once daily or placebo. A broad proteomic analysis was conducted using a proximity extension assay. Baseline and longitudinal comparisons were performed with unpaired t-test and one-way analysis of variance used to evaluate biomarker level changes. Seven candidate biomarkers were identified. Monocyte-chemotactic protein (MCP)3, pro-calcitonin/calcitonin (ProCALCA/CALCA), together with a previously identified prognostic acute GVHD biomarker, regenerating islet-derived protein (REG)3A, stratified complete responders from non-responders (participants with progressive disease) to itacitinib, but not placebo, potentially representing predictive biomarkers of itacitinib in acute GVHD. ProCALCA/CALCA, suppressor of tumorigenicity (ST)2, and tumour necrosis factor receptor (TNFR)1 were significantly reduced over time by itacitinib in responders, potentially representing response-to-treatment biomarkers. Novel biomarkers have the potential to identify patients with acute GVHD that may respond to itacitinib plus corticosteroid treatment (NCT02614612; NCT03139604).
引用
- Pratta M, Paczesny S, Socie G, et al. A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease. Br J Haematol. 2022. PMID: 35689489. doi:10.1111/bjh.18300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。